TrialInvestigational new drugs2016

Trastuzumab and bevacizumab combined with docetaxel, oxaliplatin and capecitabine as first-line treatment of advanced HER2-positive gastric cancer: a multicenter phase II study.

Didier Meulendijks et al.PubMed ↗Publisher ↗

No numbers read from the abstract.